Ranbaxy Recalls Atorvastatin Calcium Tablets Due to Glass Particulates
Ranbaxy Inc. is recalling certain lots of Atorvastatin Calcium tablets because they may contain small glass particulates.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves the presence of glass particulates in oral medication, which poses a significant risk of injury.
Plain-English summary
Ranbaxy Inc. is recalling specific lots of Atorvastatin Calcium tablets, 10 mg, 90 tablets per bottle. The recall involves 120,201 bottles distributed nationwide and in Puerto Rico. The affected lots are 2436144, 2436582, 2441567, and 2441568, with an expiration date of 08/31/2014.
The recall was initiated due to the presence of particulate matter. Certain batches of Atorvastatin tablets 10 mg, 20 mg, and 40 mg may contain small glass particulates. The FDA has classified this recall as Class II.
Consumers should check their medication for the specific lot numbers and expiration dates listed above. If the medication matches the recalled description, patients should contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Ranbaxy Inc.
- Category
- Drug — Prescription Drug
- Affected units
- 120,201
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #s: 2436144
- 2436582
- 2441567
- 2441568
- Exp 08/31/2014.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Ranbaxy Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 10 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same manufacturer · Ranbaxy Inc.
See all →- ModerateRanbaxy Recalls Absorica LD Isotretinoin Capsules Due to Undeclared Dye
FDA (Drugs) · 2015-08-12
- ModerateRanbaxy Recalls Atorvastatin Calcium Tablets Due to Foreign Tablet Presence
FDA (Drugs) · 2014-03-05
- LowRanbaxy Recalls Lac-Hydrin Lotion Due to Crystallization Texture
FDA (Drugs) · 2013-02-20
- LowRanbaxy Recalls Lac-Hydrin Cream Due to Crystallization
FDA (Drugs) · 2013-02-20
- HighRanbaxy Recalls Atorvastatin Calcium Tablets Due to Glass Particulates
FDA (Drugs) · 2012-12-05
Same hazard · glass particulates
See all →- HighEquate Cherry Cough Drops recalled for potential glass and silicone contamination
FDA (Drugs) · 2024-02-28
- SevereQuVa Pharma Recalls Fentanyl and Ropivacaine Bags Due to Glass Particulates
FDA (Drugs) · 2019-12-11
- SevereQuVa Pharma Recalls Fentanyl Injection Bags Due to Glass Particulates
FDA (Drugs) · 2019-12-11
- SevereQuVa Pharma Recalls Fentanyl and Bupivacaine Infusion Due to Glass Particulates
FDA (Drugs) · 2019-12-11
- CriticalPfizer Recalls Sodium Bicarbonate Injection Vials Due to Glass Particulates
FDA (Drugs) · 2019-04-10